Product Description
TRPM8 antagnonist (peipheral neuropathic pain); MT-8554 (Sourced from: https://www.mt-pharma.co.jp/e/develop/pipeline.html)
Mechanisms of Action: TRPM8 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mitsubishi Tanabe
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Migraine Disorders
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06848075 |
K-304 P001 | P2 |
Completed |
Migraine Disorders |
2025-08-11 |
12% |
2025-09-04 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/07/2026 |
News Article |
Kallyope Announces 2026 Strategic Priorities for Migraine and Metabolism Portfolio Based on Novel Neural Circuits Platform |
|
12/17/2025 |
News Article |
Kallyope To Present at the 44th Annual J.P. Morgan Healthcare Conference |
|
12/08/2025 |
News Article |
Kallyope Announces Positive Results from Phase 2b Study of Elismetrep for the Acute Treatment of Migraine |
|
11/12/2020 |
News Article |
Global Vasomotor Symptoms Market Insight, Epidemiology and Market Forecast Report 2017-2030 - ResearchAndMarkets.com |